84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]李文浩,牛逸群,譚明生.基于數(shù)據(jù)挖掘法探討中醫(yī)藥治療脊髓型頸椎病的用藥規(guī)律[J].中醫(yī)正骨,2021,33(01):22-26.
　LI Wenhao,NIU Yiqun,TAN Mingsheng.A study of medication rule of Traditional Chinese Medicine for treatment of cervical spondylotic myelopathy based on data mining approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(01):22-26.
點擊復(fù)制

基于數(shù)據(jù)挖掘法探討中醫(yī)藥治療脊髓型頸椎病的用藥規(guī)律()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第33卷
期數(shù):
2021年01期
頁碼:
22-26
欄目:
文獻(xiàn)研究
出版日期:
2021-01-20

文章信息/Info

Title:
A study of medication rule of Traditional Chinese Medicine for treatment of cervical spondylotic myelopathy based on data mining approach
作者:
李文浩1; 牛逸群2; 譚明生1
(1.中日友好醫(yī)院,北京 100029; 2.北京中醫(yī)藥大學(xué),北京 100029)
Author(s):
LI Wenhao1; NIU Yiqun2; TAN Mingsheng1
1.China-Japan Friendship Hospital,Beijing 100029,China2.Beijing University of Chinese Medicine,Beijing 100029,China
關(guān)鍵詞:
頸椎病;  中醫(yī)藥學(xué)文獻(xiàn);  組方原則;  數(shù)據(jù)挖掘;  方劑分析; 計算機(jī)輔助;  聚類分析
Keywords:
cervical spondylosis;  med pharmacol literature TCM;  formula composing principles;  data mining;  formula anal; comput assist;  cluster analysis
摘要:
目的:探討中醫(yī)藥治療脊髓型頸椎病的用藥規(guī)律。方法:通過計算機(jī)檢索中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫、中國知網(wǎng)、萬方數(shù)據(jù)庫、維普網(wǎng)、Cochrane Library、PubMed及EMbase數(shù)據(jù)庫從建庫至2020年1月收錄的中醫(yī)藥治療脊髓型頸椎病的文獻(xiàn),按照納排標(biāo)準(zhǔn)篩選文獻(xiàn),將篩選出的方劑的相關(guān)數(shù)據(jù)錄入Microsoft Excel 2010軟件建立數(shù)據(jù)庫,分析每味藥物的使用頻次及按性味、歸經(jīng)分類后藥物的累積使用頻次; 基于中醫(yī)傳承輔助系統(tǒng)軟件(V2.5)對所選數(shù)據(jù)采用關(guān)聯(lián)分析中的Apriori算法分析常見組方規(guī)律,采用聚類分析法演化出核心組方及新方組合。結(jié)果:共篩選出127首方劑,其中使用頻次居于前3位的中藥依次為當(dāng)歸、黃芪、川芎,藥性多偏溫,藥味偏甘、辛,歸經(jīng)以肝、脾、心、腎為主; 分析出常用中藥組合15個,挖掘出26個核心組合、13個新方組合。結(jié)論:中醫(yī)藥治療脊髓型頸椎病,多用性偏溫,味偏甘、辛,入肝、脾、心、腎經(jīng)的中藥; 多以補(bǔ)陽還五湯為核心進(jìn)行加減組方; 核心組方和新方組合可為臨床遣方用藥提供參考,但其療效有待進(jìn)一步研究。
Abstract:
To explore the medication rule of Traditional Chinese Medicine(TCM)for treatment of cervical spondylotic myelopathy(CSM).Methods:All articles about TCM for treatment of CSM included from database establishing to January 2020 were retrieved from Chinese biomedical literature database,China national knowledge internet,WanFang database,VIP database,Cochrane Library,PubMed and EMbase Database through computer.The articles were screened according to the inclusion and exclusion criterias of the articles.The TCM prescriptions involved in the articles that met the requirements were search out,and their information were inputed into Microsoft Excel 2010 software to build the database.The usage frequency of each drug and the accumulated usage frequency of drugs that were classificated according to property and flavour and meridian distribution were analyzed repectively.Based on TCM inheritance support system(TCMISS)software(V2.5),the common medication rules were searched out through analyzing the selected data by using Apriori algorithm in association analysis and the core prescriptions and new prescription combinations were obtained by using cluster analysis.Results:One hundred and twenty-seven TCM prescriptions were searched out,and the top 3 Chinese drugs with high usage frequency included angelica sinensis,astragalus membranaceus and ligusticum chuanxiong in turn.The drug property presented mainly with warm,and the drug flavours presented mainly with sweet and pungent,and the meridian distributions presented mainly with liver meridian,spleen meridian,heart meridian and kidney meridian.Fifteen common TCM combinations,26 core TCM combinations and 13 new TCM prescription combinations were obtained.Conclusion:In TCM for treatment of CSM,the drug property presented mainly with warm,and the drug flavours presented mainly with sweet and pungent,and the meridian distributions presented mainly with liver meridian,spleen meridiank,heart meridian and kidney meridian.Buyang Huanwu Tang(補(bǔ)陽還五湯)was usually used as the core of TCM combinations.The core TCM combinations and new TCM prescription combinations can provide reference for clinical medication,while their curative effects need to be further studied.

參考文獻(xiàn)/References:

[1] 裴福興,陳安民.骨科學(xué)[M].北京:人民衛(wèi)生出版社,2016:394.
[2] KALSI-RYAN S,KARADIMAS S K,FEHLINGS M G.Cervical spondylotic myelopathy:the clinical phenomenon and the current pathobiology of an increasingly prevalent and devastating disorder[J].Neuroscientist,2013,19(4):409-421.
[3] BOOGAARTS H D,BARTELS R H.Prevalence of cervical spondylotic myelopathy[J].Eur spine,2015,24(Suppl 2):139-141.
[4] 宋立人,洪恂,丁旭亮,等.現(xiàn)代中藥學(xué)大辭典[M].北京:人民衛(wèi)生出版社,2001:1-2488.
[5] 高學(xué)敏.中藥學(xué)[M].北京:中國中醫(yī)藥出版社,2007:51-502.
[6] 唐仕歡,陳建新,楊洪軍,等.基于復(fù)雜系統(tǒng)熵聚類方法的中藥新藥處方發(fā)現(xiàn)研究思路[J].世界科學(xué)技術(shù)-中醫(yī)藥現(xiàn)代化,2009,11(2):225-228.
[7] 李曦,張麗宏,王曉曉,等.當(dāng)歸化學(xué)成分及藥理作用研究進(jìn)展[J].中藥材,2013,36(6):1023-1028.
[8] 茶曉鋒,周琴.黃芪多糖對脊髓損傷大鼠脊髓運動神經(jīng)元組織形態(tài)及自噬相關(guān)蛋白表達(dá)水平的影響[J].四川中醫(yī),2019,37(10):46-50.
[9] 吳賢良,王小勇,黃建軍.川芎嗪對急性脊髓損傷患者術(shù)后神經(jīng)功能恢復(fù)的影響[J].山東醫(yī)藥,2019,59(29):67-69.
[10] 劉文雅,王曙東.地龍藥理作用研究進(jìn)展[J].中國中西醫(yī)結(jié)合雜志,2013,33(2):282-285.
[11] 郭馬瓏,朱新華,崔宏勛,等.疏通督脈手術(shù)聯(lián)合補(bǔ)陽還五湯治療脊髓型頸椎病的臨床觀察[J].中國中醫(yī)骨傷科雜志,2018,26(2):53-54.
[12] 陳夢霞,郭遂群,李新軍.椎體次全切除減壓融合術(shù)聯(lián)合補(bǔ)陽還五湯治療雙節(jié)段脊髓型頸椎病臨床觀察[J].實用中醫(yī)藥雜志,2017,33(10):1190-1191.
[13] 倪慧英,張一鳴,張學(xué)民.頸前路手術(shù)配合補(bǔ)陽還五湯薰蒸治療脊髓型頸椎病[J].中醫(yī)正骨,2014,26(2):34-37.
[14] 周峻,熊振成,董春科,等.椎管減壓聯(lián)合補(bǔ)陽還五湯治療脊髓型頸椎病的臨床研究[J].中華中醫(yī)藥學(xué)刊,2020,38(2):135-139.
[15] 陳曉東,翟明玉,歐傳雙,等.補(bǔ)氣通絡(luò)法對脊髓型頸椎病術(shù)后Aβ蛋白、ET及NO表達(dá)的影響[J].中國中醫(yī)骨傷科雜志,2018,26(4):18-23.
[16] 林曉敏,潘偉濱,吳玉瓊,等.補(bǔ)陽還五湯對脊髓損傷后Ⅰ型膠原蛋白和Ⅳ型膠原蛋白表達(dá)的影響[J].中國組織工程研究,2019,23(31):4986-4991.
[17] 羅金鑫,黃勇.補(bǔ)陽還五湯含藥血清對少突膠質(zhì)前體細(xì)胞分化的影響[J].廣州中醫(yī)藥大學(xué)學(xué)報,2018,35(6):1073-1078.
[18] 范瑜潔,聶穎,陳安,等.補(bǔ)陽還五湯對脊髓損傷大鼠紅核神經(jīng)元L-型鈣通道的影響[J].中醫(yī)藥導(dǎo)報,2018,24(20):26-29.
[19] 喬若飛,李俊杰,梁舒涵,等.補(bǔ)陽還五湯對SD大鼠脊髓損傷后HIF-1α、VEGF表達(dá)的影響[J].中醫(yī)藥導(dǎo)報,2018,24(14):30-34.
[20] 齊英娜.補(bǔ)陽還五湯對督脈瘀阻型脊髓損傷內(nèi)質(zhì)網(wǎng)應(yīng)激和血小板活化因子的影響[D].北京:北京中醫(yī)藥大學(xué),2018.

相似文獻(xiàn)/References:

[1]孫獻(xiàn)武,于香蘭,邵海燕,等.應(yīng)用三維動靜態(tài)平衡康復(fù)模式治療 非脊髓型頸椎病的臨床研究[J].中醫(yī)正骨,2015,27(11):8.
　SUN Xianwu,YU Xianglan,SHAO Haiyan,et al.Clinical study on three-dimensional dynamic and static equilibrium rehabilitation modality in the treatment of non-myelopathy type cervical spondylosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(01):8.
[2]江建春.神經(jīng)根型頸椎病的中醫(yī)藥治療研究概況[J].中醫(yī)正骨,2015,27(11):71.
[3]韋英成,董彤,吳肖梅,等.推拿手法治療神經(jīng)根型頸椎病的研究進(jìn)展[J].中醫(yī)正骨,2015,27(10):65.
[4]張莉,秦丹霞,張細(xì)姣.Orem自理理論在前路手術(shù)治療脊髓型頸椎病 圍手術(shù)期護(hù)理中的應(yīng)用[J].中醫(yī)正骨,2015,27(09):75.
[5]邸保林,董國順,林紅猛.俯臥斜扳法治療神經(jīng)根型頸椎病[J].中醫(yī)正骨,2015,27(07):70.
[6]白玉,王愛國.郭春園教授治療頸椎病的學(xué)術(shù)思想探究[J].中醫(yī)正骨,2015,27(02):64.
[7]郝慶英,劉楚吟,付嬋娟,等.Hybrid手術(shù)治療脊髓型頸椎病的護(hù)理[J].中醫(yī)正骨,2015,27(02):78.
[8]王翔,詹紅生,張明才,等.石氏手法治療神經(jīng)根型頸椎病的療效觀察[J].中醫(yī)正骨,2015,27(04):12.
　WANG Xiang,ZHAN Hongsheng,ZHANG Mingcai,et al.Observation on the curative effect of Shi's manipulation in the treatment of cervical spondylotic radiculopathy[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(01):12.
[9]史俊德,梁舒涵,海淵.毛書歌教授治療寰樞關(guān)節(jié)錯縫的經(jīng)驗[J].中醫(yī)正骨,2015,27(04):76.
[10]王樹強(qiáng),楊振國,劉文斌,等.董建文教授治療神經(jīng)根型頸椎病的經(jīng)驗[J].中醫(yī)正骨,2015,27(01):69.

備注/Memo

備注/Memo:
基金項目:國家自然科學(xué)基金項目(81873141)
通訊作者:譚明生 E-mail:[email protected]
更新日期/Last Update: 2021-01-20